CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate of 5.20% for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2025 was 5.20%, a 10.64% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2024 was 4.70%, a 2.08% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2023 was 4.80%, a 166.67% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2022 was 1.80%, a 20.00% increase from fiscal 2021.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 12 month | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 12 month as first filed |
|---|---|---|
| 2025-12-27 | 5.20% 10-K · filed 2026-02-18 | |
| 2024-12-28 | 4.70% 10-K · filed 2026-02-18 | |
| 2023-12-30 | 4.80% 10-K · filed 2026-02-18 | |
| 2022-12-31 | 1.80% 10-K · filed 2025-02-19 | |
| 2021-12-25 | 1.50% 10-K · filed 2024-02-14 | |
| 2020-12-26 | 2.10% 10-K · filed 2023-02-22 | 2.14% 10-K · filed 2021-02-17 |
| 2019-12-28 | 3.20% 10-K · filed 2022-02-16 | 3.21% 10-K · filed 2020-02-11 |
| 2018-12-29 | 2.82% 10-K · filed 2021-02-17 | |
| 2017-12-30 | 3.01% 10-K · filed 2020-02-11 | |
| 2016-12-31 | 3.89% 10-K · filed 2019-02-13 | |
| 2015-12-26 | 3.75% 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |